C15 vs Omega-3: Which Is Better for Heart Health?
Should I take C15:0 instead of omega-3?
No. Omega-3 scores 6.8 and C15:0 4.9, and the evidence gap is larger than the score gap. C15:0 has two small human trials. Omega-3 has outcome trials, prescription forms and guideline standing. C15:0 wins a few low-scoring rows where neither has real trial data behind it.
- Omega-3 6.8, C15:0 4.9. On evidence the gap is 4.0 against 1.6 and on efficacy 3.4 against 1.4.
- C15:0 has two direct human RCTs total: Robinson 2024 with 30 people and TANGO (Chooi 2024) with 88, where the diet drove the fatty-liver result.
- The causal cardiovascular case failed. Steffen 2026 in CARDIA and ARIC found modest observational associations, no incident cardiovascular disease association and no Mendelian randomisation support.
- Essentiality is not established. Ciesielski 2024 explicitly frames C15:0 essentiality as controversial and needing more evidence.
- Omega-3 is not a cure-all either. Cochrane 2020 pooled 162,796 participants and found little or no effect on all-cause mortality, stroke or broad cardiovascular events.
- Where omega-3 does deliver is narrow and real: triglycerides, prenatal DHA, EPA-dominant depression and rheumatoid arthritis pain.
- Cost runs the wrong way for C15:0: $40 to $50 a month on subscription against $20 to $40 for a credible fish oil.
- Both have a real safety line. High-dose EPA and DHA raise atrial fibrillation risk, and C15:0 has a preclinical maternal glucose-intolerance signal that puts pregnancy on its contraindication list.
At a Glance
C15 (Pentadecanoic Acid)
- Efficacy 1.4
- Breadth 1.6
- Evidence 1.6
- Speed 2.0
- Durability 2.0
- Bioindividuality 1.8
- Safety Risk 1.6
- Side Effects 1.4
- Cost 3.5
- Effort 1.2
- Opportunity Cost 3.8
- Dependency 1.2
- Reversibility 1.2
- Liver Detox
- Metabolic Health
- Cardiovascular
- Anti Inflammatory
Pentadecanoic acid, a saturated odd-chain fat sold by subscription. BioHarmony 4.9, neutral.
Omega-3
- Efficacy 3.4
- Breadth 3.8
- Evidence 4.0
- Speed 2.7
- Durability 2.0
- Bioindividuality 3.5
- Safety Risk 2.3
- Side Effects 2.0
- Cost 2.0
- Effort 1.0
- Opportunity Cost 2.0
- Dependency 1.5
- Reversibility 1.0
- Prenatal
- Depression
- Cardiovascular
- Metabolic Health
EPA and DHA from marine or algal oil. BioHarmony 6.8, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Prenatal | Omega-3 | Omega-3 7.0 against C15:0's 2.5, the widest gap in the matrix and the only row where one side has a genuine standard of care. Purified DHA or algae oil after clinician review is a named best-for use on the omega-3 report.C15:0 runs the other way: Wang 2024 found pentadecanoic acid induced mild maternal glucose intolerance and promoted offspring growth in mice, which is why pregnancy, lactation and planned conception are all on its contraindication list. |
| Cardiovascular | Omega-3 | Omega-3 6.0 against 4.0, and both sides deserve their caveats. REDUCE-IT (Bhatt 2019) showed prescription EPA lowering cardiovascular events in selected high-risk patients with hypertriglyceridemia, while STRENGTH (Nicholls 2020) was null for high-dose EPA plus DHA against corn oil and Cochrane 2020 found little or no broad effect across 162,796 people.C15:0's cardiovascular case was tested and did not survive: Steffen 2026 found no incident cardiovascular disease association and no Mendelian randomisation support in CARDIA and ARIC. |
| Metabolic Health | Omega-3 | Omega-3 6.0 against C15:0's 4.0. Zhang 2025 pooled 23 RCTs in 2,061 participants with reduced triglycerides and total cholesterol, though no significant plaque-volume effect, and MARINE (Bays 2011) is the triglyceride-lowering anchor in very high triglycerides. C15:0's metabolic evidence is Sun 2025, which is an erythrocyte biomarker association study rather than a supplement trial. |
| Anti Inflammatory | Omega-3 | Omega-3 6.0 against 4.0, on a real mechanism and a real umbrella review. EPA and DHA displace arachidonic acid in membranes and feed specialised pro-resolving mediator production, and Kaviani 2022 found CRP, IL-6 and TNF-alpha reductions supporting a modest anti-inflammatory effect. C15:0's inflammatory case is mechanistic modelling rather than measured markers in people. |
| Liver Detox | Omega-3 | Omega-3 6.0 against C15:0's 4.5, and this is the closest of omega-3's wins because it is where C15:0 was actually tested.TANGO (Chooi 2024) randomised 88 people to an Asian-adapted Mediterranean diet with or without pentadecanoic acid, and the diet drove the fatty-liver improvement with C15:0 as an adjunct signal. The AASLD practice guidance does not name C15:0 as a therapy for fatty liver disease. |
| Blood Sugar | C15 (Pentadecanoic Acid) | C15:0 4.0 against omega-3's 2.0, and read the number rather than the winner. Both sit in the lower half of the scale, and C15:0's glucose case is mechanistic, resting on AMPK activation and partial PPAR-alpha and PPAR-delta agonism rather than on a glycemic endpoint.Robinson 2024 raised circulating C15:0 in 30 people over 12 weeks with exploratory liver-enzyme and hemoglobin signals, not glucose outcomes. |
| Cellular Senescence | C15 (Pentadecanoic Acid) | C15:0 3.5 against omega-3's 2.0, on mechanism alone. The proposed route is membrane stabilisation and ferroptosis suppression alongside mTOR, JAK-STAT and HDAC6 inhibition, and that mechanism block carries an "estimated" provenance on its own report rather than an extracted one. No human trial in either report measured a senescence endpoint. |
| Body Composition | C15 (Pentadecanoic Acid) | C15:0 3.5 against 2.5. Neither is a body-composition intervention and neither has a trial with that endpoint. This row is the clearest example of why the win list matters less than the scores: a one-point edge between 3.5 and 2.5 is two weak options, not a recommendation. |
| Mitochondrial | Tie | Both 3.0. C15:0's report proposes mitochondrial membrane potential restoration as part of its mechanism, and omega-3 reaches mitochondria indirectly through membrane phospholipid composition. Neither claim has a human trial with a mitochondrial endpoint in either evidence list. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| C15:0 (pentadecanoic acid) | $40 to $50 | ESTIMATE, priced 2026-09-08, direct subscription. The fatty15 90-day subscription is $119.95 for 270 capsules at 200 mg a day, about $1.33 a day or roughly $40 a month, with the 30-day trial kit at $49.95 setting the high end. Generic pentadecanoic acid capsules exist at retail and are less consistently characterised for purity. |
| Omega-3 (EPA and DHA) | $20 to $40 | Extracted from the source report rather than estimated, priced 2026-09-08, retail. That buys a credible fish oil at 1 to 2 g a day of combined EPA and DHA. Premium re-esterified triglyceride or krill products run $40 to $80 and prescription EPA far more. The spend-up is for freshness and accurate labeling rather than for access. |
| The difference | About $10 to $20 a month, in the wrong direction | The newer molecule with two small trials costs more than the older one with outcome trials, prescription forms and a guideline footprint. C15:0's cost subrating is 3.5 against omega-3's 2.0, and its opportunity-cost subrating is 3.8, the highest number on its report.That opportunity-cost figure is the honest summary of this comparison. Money spent on a C15:0 subscription is money not spent on the intervention with the evidence, and the source report's own caution is that C15:0 should never substitute for guideline-backed cardiovascular, diabetes, liver or cognitive care. |
When to Switch
Omega-3 runs on the longer clock of the two: a first noticeable change at about 2 weeks, full effect at 16 weeks and a 16-week assessment window, because the endpoint is membrane composition and the Omega-3 Index takes months to move.
C15:0's report gives it a 12-week window with first change at 4 weeks and full effect at 12, which matches the length of the Robinson 2024 trial rather than a measured onset.
Start with omega-3 in essentially every case, and start by asking whether you need a supplement at all. The best route is food: sardines, mackerel, wild salmon and fish roe.
If you supplement, the honest indication list is narrow: a documented Omega-3 Index below 5%, elevated triglycerides under clinician direction, EPA-dominant support for unipolar depression, rheumatoid arthritis pain, or prenatal DHA. Broad longevity and general cardiovascular prevention are not on that list, because Cochrane 2020 tested them across 162,796 people and found little or no effect.
Consider C15:0 only in the one population its own report names: adults who eat no dairy fat, follow vegan or low-dairy diets, have measured low circulating C15:0, and want a structured 12-week experiment with baseline labs.
That is a narrow, testable case. It is not a fish-oil replacement, and swapping omega-3 for it means giving up the triglyceride, prenatal and depression evidence in exchange for two small trials.
Stop either one for the same class of reason. High-dose EPA and DHA raise atrial fibrillation risk, concentrated in high-cardiovascular-risk participants per Abuknesha 2025, so anyone with atrial fibrillation or high risk should stay at or below 1 g a day.
C15:0 should be stopped if the marker you chose does not move by 12 weeks, and it should not be run chronically at high dose without repeat lipid and liver labs.
Who Should Pick What?
You want one fat supplement and eat little oily fish
Omega-3
Omega-3, and food first. A documented Omega-3 Index below 5% is the cleanest indication, and sardines, mackerel, wild salmon and fish roe do the job without a capsule. If you supplement, buy for freshness and accurate EPA and DHA labeling, because oxidised oil is the main failure mode.
Pregnant or planning a pregnancy
Omega-3
Prenatal 7.0 against 2.5, the clearest row here. Purified DHA or algae oil after clinician review is a named best-for use. C15:0 goes the other way: Wang 2024 found mild maternal glucose intolerance and promoted offspring growth in mice, and pregnancy, lactation and planned conception are all contraindications on its report.
Elevated triglycerides, working with a clinician
Omega-3
Metabolic health 6.0 against 4.0. MARINE (Bays 2011) is the triglyceride anchor in very high triglycerides and REDUCE-IT (Bhatt 2019) showed prescription EPA lowering events in selected high-risk patients. Note the trade in that trial: more atrial fibrillation hospitalisation. This is a prescription conversation, not a supplement aisle one.
Vegan or low-dairy, with measured low circulating C15:0
C15 (Pentadecanoic Acid)
This is the one population C15:0's own report names, and the framing is a 12-week experiment rather than a subscription. Take baseline labs, run 200 mg a day, and stop if the marker you chose stays flat. Use direct EPA and DHA algae oil alongside rather than instead, because C15:0 does not supply what omega-3 supplies.
Hoping C15:0 replaces fish oil
Omega-3
It does not. C15:0 loses cardiovascular, metabolic health, anti-inflammatory, liver and prenatal, and Ciesielski 2024 explicitly frames its essentiality as controversial and requiring more evidence. Steffen 2026 tested the causal cardiovascular case in CARDIA and ARIC and found no incident disease association and no Mendelian randomisation support.
Atrial fibrillation, or high atrial fibrillation risk
C15 (Pentadecanoic Acid)
Not as a recommendation, but because omega-3 has a specific dose-dependent problem for you. Abuknesha 2025 pooled 34 RCTs in 114,326 participants and found atrial fibrillation risk concentrated in high-cardiovascular-risk people on high-dose EPA and DHA. Doses above 1 g a day are a contraindication on its report. Below that threshold, omega-3 is still the better molecule.
Rheumatoid arthritis or inflammatory chronic pain
Omega-3
Anti-inflammatory 6.0 against 4.0, with Gkiouras 2022 supporting lower disease activity indicators and reduced NSAID uptake in rheumatoid arthritis, and Xie 2025 pooling 41 RCTs in 3,759 participants with improved chronic pain intensity. C15:0 has nothing comparable.
On an anticoagulant, or surgery within two weeks
C15 (Pentadecanoic Acid)
Again not an endorsement, just that omega-3 is contraindicated for you at high dose: therapeutic anticoagulant or antiplatelet therapy without clinician oversight, bleeding disorder, and any invasive procedure within two weeks. C15:0's exclusions are different: pregnancy, lactation, pediatric use, and chronic high-dose use without repeat lipid and liver labs.
Research Highlights
-
Mechanism Difference
These two fats do different structural jobs and are not interchangeable. EPA and DHA incorporate into membrane phospholipids where they displace arachidonic acid, feed specialised pro-resolving mediator production, activate PPAR-alpha and damp NF-kB, which is how they lower triglycerides and resolve inflammation.C15:0 is a saturated odd-chain fat proposed to stabilise cell membranes while acting as a partial PPAR-alpha and PPAR-delta agonist, an AMPK activator and an inhibitor of mTOR, JAK-STAT and HDAC6. The one shared node is PPAR-alpha. That mechanism block carries an estimated rather than extracted provenance on its own report, which is the right way to read it.
-
Evidence Gap
The evidence subratings are 4.0 for omega-3 and 1.6 for C15:0, and the trial counts explain why. C15:0 has two direct human RCTs: Robinson 2024 in 30 young adults with overweight or obesity, which raised circulating C15:0 with exploratory liver-enzyme and hemoglobin signals, and TANGO (Chooi 2024) in 88 people, where the Asian-adapted Mediterranean diet drove the fatty-liver improvement.Omega-3's list includes a Cochrane review of 162,796 participants, a cardiovascular outcome trial in REDUCE-IT, its null counterpart in STRENGTH, and pooled analyses in depression, chronic pain, rheumatoid arthritis and atrial fibrillation risk. More evidence has also meant more disproved claims, which is what a mature evidence base looks like.
-
Cost Comparison
C15:0 runs $40 to $50 a month on the branded 200 mg a day subscription, an estimate from the fatty15 90-day price of $119.95 for 270 capsules. A credible fish oil at 1 to 2 g a day of combined EPA and DHA runs $20 to $40, extracted from the source report. Both priced 2026-09-08.So the option with two small trials costs more than the option with outcome trials. C15:0's opportunity-cost subrating is 3.8, the highest number on its report, and its own verdict warns against using it as a substitute for guideline-backed cardiovascular, diabetes, liver or cognitive care.
-
Editorial Verdict
Omega-3 scores 6.8 and C15:0 4.9, and omega-3 takes prenatal, cardiovascular, metabolic health, anti-inflammatory and liver. C15:0's three wins, blood sugar, cellular senescence and body composition, all sit between 3.5 and 4.0, which means two weak options rather than one good one.C15:0 is being marketed as the first essential fatty acid discovered in 90 years, which positions it as a fish-oil replacement. Ciesielski 2024 frames that essentiality as controversial and needing more evidence, and Steffen 2026 found no causal cardiovascular support. Buy the fish oil, or better, eat the fish.
-
What Omega 3 Does Not Do
Omega-3 winning this comparison is not the same as omega-3 working for everything, and its own report is blunt about that. Cochrane 2020 pooled 162,796 participants and found little or no effect on all-cause mortality, stroke or broad cardiovascular events. STRENGTH (Nicholls 2020) was null for high-dose EPA plus DHA against corn oil.Appleton 2021 judged the depression effect small to modest and low or very low certainty. Liu 2025 found no significant pain or quality-of-life benefit in endometriosis despite lower inflammatory cytokines, and Norouzzadeh 2026 found no pulse-wave-velocity effect across 20 RCTs. The real indications are narrow: triglycerides, prenatal DHA, EPA-dominant depression, rheumatoid arthritis pain.
-
Safety Comparison
Omega-3 scores 2.3 on safety risk against C15:0's 1.6, and that gap is one specific dose-dependent finding rather than general toxicity. Abuknesha 2025 pooled 34 RCTs in 114,326 participants and found atrial fibrillation risk concentrated in high-cardiovascular-risk people receiving high-dose EPA and DHA, which is why doses above 1 g a day are contraindicated in atrial fibrillation or high risk.C15:0's exclusions are mostly about the absence of data rather than the presence of harm: pregnancy, lactation, planned conception and pediatric use, with Wang 2024's mouse maternal glucose-intolerance signal behind the reproductive entries. Chronic high-dose use without repeat lipid and liver labs is the other listed caution.
Frequently Asked Questions
- Is C15:0 better than fish oil?
- No. Omega-3 scores 6.8 against C15:0's 4.9 and wins prenatal, cardiovascular, metabolic health, anti-inflammatory and liver. The evidence subratings are 4.0 against 1.6, because C15:0 has two direct human RCTs totalling 118 participants while omega-3 has outcome trials and a Cochrane review of 162,796 people.
- Is C15:0 really an essential fatty acid?
- That is the marketing claim and it is not settled. Ciesielski 2024 is a mechanistic review that explicitly frames C15:0 essentiality as controversial and requiring more evidence. Essentiality means your body cannot make enough and deficiency causes disease, and neither half of that has been demonstrated in people.
- Does C15:0 help your heart?
- The causal case was tested and did not hold. Steffen 2026 analysed plasma pentadecanoic acid in the CARDIA and ARIC cohorts and found modest observational associations, no association with incident cardiovascular disease, and no Mendelian randomisation support. Observational association with a dairy-fat biomarker is not the same as the supplement doing something.
- Do I need an omega-3 supplement at all?
- Only for specific reasons. The honest indication list is a documented Omega-3 Index below 5%, elevated triglycerides under clinician direction, EPA-dominant support for unipolar depression, rheumatoid arthritis pain, or prenatal DHA. Cochrane 2020 tested broad prevention across 162,796 people and found little or no effect. Oily fish and fish roe cover most people without a capsule.
- How much omega-3 is too much?
- Above 1 g a day is where the atrial fibrillation signal appears, and it is concentrated in people at high cardiovascular risk. Abuknesha 2025 pooled 34 RCTs in 114,326 participants showing that pattern, and REDUCE-IT itself recorded more atrial fibrillation hospitalisation. Anyone with atrial fibrillation or high risk should stay at or below 1 g a day.
- Who should actually consider C15:0?
- One narrow group, named on its own report: adults who eat no dairy fat, follow vegan or low-dairy diets, have measured low circulating C15:0, and want a structured 12-week experiment with baseline labs and a stop rule. Not pregnant or breastfeeding, not planning conception, not children, and not as a replacement for guideline-backed care.
- How long before either one works?
- Omega-3 gives a first noticeable change at about 2 weeks with full effect at 16 weeks and a 16-week assessment window, because membrane composition and the Omega-3 Index take months to shift. C15:0's window is 12 weeks with full effect at 12, which matches the length of the Robinson 2024 trial rather than a measured onset.
- What should I look for when buying fish oil?
- Freshness above everything. Marine oils oxidise, and an oxidised capsule delivers rancid fat rather than EPA and DHA, which is why the omega-3 report flags purity verification as required. Check accurate EPA and DHA labeling and low peroxide values, and IFOS certification is the practical shortcut.
Evidence Sources
- RCT Pentadecanoic acid supplementation in young adults with overweight and obesity, randomized controlled trial (2024) 30 participants, 12 weeks at 200 mg a day. Raised circulating C15:0 with exploratory liver-enzyme and hemoglobin signals.
- RCT Asian-adapted Mediterranean diet and pentadecanoic acid in fatty liver disease (TANGO) (2024) 88 participants. The diet drove the main fatty-liver improvement, with C15:0 as an adjunct signal.
- Observational Plasma pentadecanoic acid in CARDIA and ARIC: observational associations without evidence of causality (2026) Modest observational associations, no incident cardiovascular disease association, and no Mendelian randomisation support.
- Meta-analysis Erythrocyte odd-chain fatty acids and risk of cardiometabolic diseases (2025) Prospective and meta-analytic biomarker evidence. Observational rather than a C15:0 supplement trial.
- Review New insights on pentadecanoic acid, with focus on its controversial essentiality (2024) Explicitly frames C15:0 essentiality as controversial and requiring more evidence.
- Animal study Pentadecanoic acid induces mild maternal glucose intolerance and promotes offspring growth in mice (2024) Preclinical pregnancy and developmental caution. Not human supplement safety evidence.
- Guideline Practice guidance for nonalcoholic fatty liver disease, AASLD (2026) C15:0 is not a named guideline therapy for fatty liver disease.
- Review Save your money on Fatty15, CSPI Nutrition Action (2024) Independent consumer-health criticism of the product's claims and business model.
- Systematic review Omega-3 intake for cardiovascular disease, Cochrane review (2020) 162,796 participants. Little or no effect on all-cause mortality, stroke or broad cardiovascular events.
- RCT Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT) (2019) Prescription EPA lowered cardiovascular events in selected high-risk patients, with more atrial fibrillation hospitalisation.
- RCT High-dose omega-3 fatty acids versus corn oil on major adverse cardiovascular events (STRENGTH) (2020) High-dose EPA plus DHA carboxylic acid was null against corn oil.
- RCT Eicosapentaenoic acid ethyl ester therapy in very high triglycerides (MARINE) (2011) Triglyceride-lowering efficacy in very high triglycerides.
- Meta-analysis Omega-3 intake on lipid metabolism and plaque volume in coronary heart disease (2025) 23 RCTs, 2,061 participants. Reduced triglycerides and total cholesterol, no significant plaque-volume effect.
- Meta-analysis Effects of omega-3 fatty acid treatment on risk for atrial fibrillation (2025) 34 RCTs, 114,326 participants. Atrial fibrillation risk concentrated in high-cardiovascular-risk participants on high-dose EPA and DHA.
- Meta-analysis Omega-3 supplementation on inflammatory biomarkers, umbrella meta-analysis (2022) CRP, IL-6 and TNF-alpha reductions supporting a modest anti-inflammatory effect.
- Systematic review n-3 fatty acid supplementation on rheumatoid arthritis disease activity indicators (2022) Lower disease activity indicators and reduced NSAID uptake.
- Meta-analysis Effects of omega-3 fatty acids on chronic pain, systematic review and meta-analysis (2025) 41 RCTs, 3,759 participants. Chronic pain intensity improved overall, with subgroup variation.
- Meta-analysis Omega-3 supplementation for major depressive disorder, meta-analysis and meta-regression (2016) 13 studies, 1,233 participants. Modest benefit with an EPA dose association.
- Systematic review Omega-3 fatty acids for depression in adults, Cochrane review (2021) Small to modest effect judged low or very low certainty and unlikely to be clinically meaningful overall.
- Meta-analysis Effect of omega-3 polyunsaturated fatty acid on endometriosis (2025) 5 RCTs, 424 participants. No significant pain or quality-of-life benefit despite lower inflammatory cytokines.
- Meta-analysis Omega-3 supplementation and vascular health biomarkers (2026) 20 RCTs, 1,208 participants. No significant pulse-wave-velocity effect and mixed vascular biomarker findings.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- C15:0 Pentadecanoic acid
- A saturated fatty acid with an odd number of carbons, found in dairy fat. Sold as fatty15 and marketed as newly essential.
- EPA Eicosapentaenoic Acid
- The marine omega-3 behind the triglyceride and depression results. REDUCE-IT used a prescription EPA-only form.
- DHA Docosahexaenoic Acid
- The structural omega-3 concentrated in brain and retina. The form that matters in pregnancy.
- Omega-3 Index Red blood cell EPA plus DHA percentage
- The blood test that tells you whether you need to supplement. Below 5% is the cleanest indication.
- MR Mendelian Randomisation
- A genetic method for testing whether an association is causal. It found no support for C15:0's cardiovascular claim in Steffen 2026.
- PPAR-alpha Peroxisome Proliferator-Activated Receptor alpha
- A fat-sensing transcription factor regulating lipid metabolism. The one target both fats are proposed to touch.
- SPM Specialized Pro-resolving Mediators
- Molecules made from EPA and DHA that actively switch inflammation off rather than merely blocking it.
- AF Atrial Fibrillation
- An irregular heart rhythm. The main dose-dependent safety signal for high-dose EPA and DHA.
- IFOS International Fish Oil Standards
- Third-party certification for oxidation, potency and contaminants. The practical shortcut to a fish oil that is not rancid.
